International Journal of Gynecological Cancer

Papers
(The H4-Index of International Journal of Gynecological Cancer is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma813
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)201
SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer161
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer127
COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers113
World Health Organization call for action to eliminate cervical cancer globally88
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer75
Clear cell carcinoma of the ovary: a clinical and molecular perspective75
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy72
Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB–IVA: oncologic results of a prospective randomized international multicenter (Uterus-159
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-b55
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*55
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial53
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors52
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events51
Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice44
The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life44
Management of pregnancy in women with cancer43
Human papillomavirus-independent cervical cancer43
European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery43
Evaluating meaningful levels of financial toxicity in gynecologic cancers42
Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain41
Uterine serous carcinoma: key advances and novel treatment approaches38
Comparison of laparoscopic and open radical hysterectomy in cervical cancer patients with tumor size ≤2 cm37
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment follo37
Prognostic factors in patients with vulvar cancer: the VULCAN study36
SUCCOR cone study: conization before radical hysterectomy35
p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification34
Advances in immunotherapy for cervical cancer: recent developments and future directions34
Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial34
European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and s33
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes33
British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)33
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-00133
0.17076396942139